 Exact Sciences Corps NASDAQ: EXAS Q1 revenues increased 21 YY to 486.6 million, beating the average Wall Street estimate of 461.71 million. Excluding COVID-19 testing revenues, which dropped 15 to 27.4 million, Exacts Q1 revenue increased 24. 